MELBOURNE, Australia--(BUSINESS WIRE)--Nov. 17, 2005--Norwood Abbey Limited (OTC:NABYF) (ASX:NAL) today announced that its subsidiary, Norwood Immunology Limited (AIM:NIM), a company focussed on the rejuvenation of the immune system, commenced its Phase II clinical trial. This is being undertaken in collaboration with The University of Texas M D Anderson Cancer Center, of Houston, under the supervision of Dr. Patrick Hwu, Professor and Chair of Melanoma Medical Oncology. This follows the Company’s previous announcement of the signing of the trial agreement in October 2005.